R3CE (Rapid, Reproducible, Rare Cell 3D Expansion) is a clinically validated platform capable of generating single cell-derived organoids within one to four weeks. It outperforms currently 3D culture technologies in terms of yields, time to form organoids,easiness of operation. It also demonstrates similar yieldscost structure to 2D culture protocols. R3CE is ready for drug testing for all clinical samplesprovides sufficient quantity of genomic samples derived from cancer patients. It would help conduct clinical cancer treatment in the translational study.

3D cell culture technology on the market generally uses a large number of cells to aggregate into spheres. This method can culture primary tissuestem cells, but the yield is low, time-consuming,difficult to operate. While the R3CE cell culture platform, with only a small number of cells, can be derived from single cells into cell spheres within four weeks. With high yields, homogeneous in size, easy access,operation process similar to 2D cell culture experiment, R3CE 3D cell culture platform can directly apply to the drug screening.

The R3CE platform cell culture period is shorteasy to access. It is conducive to entering clinical treatmentassisting doctors in diagnosis. It will advance in conducting clinical treatmentpracticing cancer precision medicineregenerative medicine in the translational study. In addition, the R3CE technology can accelerate clinical modeling. In the short term, it can become a breakthrough in precision medicine. It aims to establish a database to provide a platform for developing biomedicine in the long term.

1.欲媒合之產業領域：生技醫藥。2.欲媒合項目：技術合作、投資合作。